Mechanisms of breast cancer cell growth & tumorigenicity

描述（由申请人提供）：越来越多的证据表明，乳腺癌肿瘤中适配蛋白p130cas （Cas）表达的变化可能导致癌症进展和预后不良。在人类乳腺肿瘤中，Cas过表达与高复发概率和对抗雌激素他莫昔芬的高内在耐药发生率相关。在培养的过表达Cas或其结合伙伴AND-34/BCAR3的乳腺癌细胞中，抗雌激素抗性也很明显。Cas由多个结构域组成，每个结构域都具有与不同蛋白质阵列相互作用的能力，从而促进潜在的不同功能结果。我们假设Cas或and -34的过表达通过与这些蛋白的特定子集相互作用激活信号通路，最终导致抗雌激素抵抗和与侵袭性肿瘤行为和不良预后相关的细胞生理学变化。这一假设将在Aim 1中通过鉴定Cas和and -34促进抗雌激素抵抗的结构域和下游效应物，并研究这些途径在这一过程中如何与雌激素受体功能协调或覆盖雌激素受体功能来验证。在Aim 2中，我们将测试作为早期乳腺癌模型的细胞中的Cas过表达是否可以诱导细胞生理和形态的变化，这些变化与获得更积极的生长和侵袭表型相一致。相反，我们还将测试作为晚期乳腺癌模型的细胞中Cas表达或功能的抑制是否会逆转这些细胞所表现出的一些有害表型。已知与上述研究中涉及的结构域结合的蛋白质的潜在功能贡献将在两个特定目标的背景下进行。然而，如果涉及的结构域没有已知的结合伙伴，或者当没有发现已知的结合蛋白起作用时，Aim 3将尝试确定其他结合伙伴并测试它们是否在这些途径中起作用。这项工作的完成将为以下领域开辟新的研究途径：开发预测他莫昔芬治疗反应的分子筛选，设计增强他莫昔芬对内在耐药患者疗效的策略，以及应用新的分子方法来减缓肿瘤进展。

DESCRIPTION (provided by applicant): There is growing evidence to suggest that changes in expression of the adapter protein p130cas (Cas) in breast tumors may contribute to cancer progression and poor prognosis. In human breast tumors, Cas overexpression is correlated with a high probability of recurrence and a high incidence of intrinsic resistance to the antiestrogen tamoxifen. Antiestrogen resistance is also evident in cultured breast cancer cells that overexpress either Cas or its binding partner AND-34/BCAR3. Cas is comprised of multiple structural domains, each of which has the capacity to interact with a different array of proteins and thus promote potentially distinct functional outcomes. We hypothesize that overexpression of Cas or AND-34 activates signaling pathways through interactions with a defined subset of these proteins, ultimately leading to antiestrogen resistance and changes in cell physiology that are associated with aggressive tumor behavior and poor prognosis. This hypothesis will be tested in Aim 1 by identifying domains and downstream effectors of Cas and AND-34 that function to promote antiestrogen resistance, and investigating how these pathways coordinate with or override estrogen receptor functions during this process. In Aim 2, we will test whether Cas overexpression in cells that serve as models for early-stage breast cancer can induce changes in cell physiology and morphology that coincide with the acquisition of a more aggressive growth and invasion phenotype. Conversely, we will also test whether inhibition of Cas expression or function in cells that serve as models for late-stage breast cancer reverses some of the deleterious phenotypes exhibited by these cells. The potential functional contribution of proteins known to bind to domains that are implicated in the studies described above will be pursued in the context of each of the two Specific Aims. However, in those instances where a domain is implicated that does not have a known binding partner, or when none of the known binding proteins are found to play a role, attempts will be made in Aim 3 to identify additional binding partners and test whether they function in these pathways. Completion of this work will open new avenues of investigation into such areas as the development of molecular screens for predicting responses to tamoxifen treatment, the design of strategies for enhancing the efficacy of tamoxifen in intrinsically resistant patients, and the application of novel molecular approaches to slow tumor progression.